ArticleMolecules (Basel, Switzerland)2019

Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.

Xia Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.